The report covers emerging Acute Ischemic Stroke drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Acute Ischemic Stroke treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Acute Ischemic Stroke: An Overview
According to the Centers for Disease Control and Prevention (CDC), a stroke happens when a blood vessel that supplies the brain with oxygen and nutrients becomes clogged by a clot or bursts (or ruptures). Brain cells die when they are deprived of the blood (and oxygen) required.
Symptoms of stroke depend on the severity and location of the stroke in the brain. Sudden onset numbness or weakness in an arm or leg, facial droop, difficulties speaking or comprehending speech, disorientation, issues with balance or coordination, and loss of vision are all indications of acute ischemic stroke. Stroke severity may be stratified based on NIHSS scores: very severe: >25; severe: 15-24; mild to moderately severe: 5-14; mild: 1-5.
Critical care specialists are important in the multidisciplinary approach used to treat AIS. Antiplatelet medication is the mainstay of care for treating stroke and transient ischemic episodes. Due to its affordability, accessibility, and relative safety, aspirin is the most extensively used medication.
Acute Ischemic Stroke Market Key Facts
-
In the 7MM, the Acute Ischemic Stroke Market size was found to be USD 1,300 million in 2022. The market is expected to grow by 2032, driven by rising incidence, better diagnosis, improved stroke care, and the launch of novel therapies.
-
The United States accounted for the largest market share (>USD 700 million) of acute ischemic stroke in 2022 because the most advanced healthcare system is providing better patient access to therapies.
-
The total EU4 (Germany, France, Italy, and Spain) and the UK market size of acute ischemic stroke were more than USD 300 million in 2022.
-
Invimestrocel (Athersys/Healios) is expected to be the most successful therapy amongst the pipeline candidates and shall account for the highest market revenue in the coming years.
-
Among the 7MM, the US accounted for the highest number of cases of acute ischemic stroke, with more than 700,000 cases in 2022, owing to the long-term psychological, physical, and social consequences among the population.
-
Among the EU4 and the UK, Germany accounted for the highest number of acute ischemic stroke cases (around 250,000). On the contrary, Spain accounted for the least cases in 2022.
-
The FDA has approved the standard gold therapy, tissue plasminogen activator, r-tPA, often known as alteplase, to treat ischemic stroke. Further, in November 2020, the US FDA approved BRILINTA to reduce the risk of stroke in patients with an acute ischemic stroke
-
Several companies are working actively on new therapies expected to bring significant change in the acute ischemic stroke market. Some of the treatments that are in the late stage of development include glenzocimab (Acticor Biotech), DM199 (DiaMedica Therapeutics), LT3001 (Lumosa Therapeutics), nerinetide (NoNO Inc.), BMS-986177/milvexian (Bristol Myers Squibb Company/Janssen Pharmaceuticals), and invimestrocel (Healios/Athersys).
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Acute Ischemic Stroke pipeline therapies. It also thoroughly assesses the Acute Ischemic Stroke market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Acute Ischemic Stroke drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Acute Ischemic Stroke Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Acute Ischemic Stroke epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Acute Ischemic Stroke epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Acute Ischemic Stroke Epidemiology, Segmented as –
-
Total Incident Cases of Acute Ischemic Stroke
-
Gender-specific Cases of Acute Ischemic Stroke
-
Age-specific Cases of Acute Ischemic Stroke
-
Type-specific Cases of Acute Ischemic Stroke
Acute Ischemic Stroke Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Acute Ischemic Stroke market or expected to be launched during the study period. The analysis covers the Acute Ischemic Stroke market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Acute Ischemic Stroke drugs based on their sale and market share.
The report also covers the Acute Ischemic Stroke pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Acute Ischemic Stroke companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Acute Ischemic Stroke Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-market
Acute Ischemic Stroke Therapeutics Analysis
Several major pharma and biotech companies are developing Acute Ischemic Stroke therapies. Currently, GNT Pharma is leading the therapeutics market with its Acute Ischemic Stroke drug candidates in the most advanced stage of clinical development.
Acute Ischemic Stroke Companies Actively Working in the Therapeutics Market Include
AbbVie, Acticor Biotech, Angde Biotech Pharmaceutical, aptaTargets, Athersys|Healios K.K., Bayer, Biogen Inc., Bristol-Myers Squibb, Clinuvel Pharmaceuticals, DiaMedica Therapeutics, Genentech, Inc., GNT Pharma, Healios, Janssen Pharmaceutical, JCR Pharmaceuticals, Lumosa Therapeutics, NC Medical Research, NoNO Inc., NuvOx Pharma, Pharmazz, Pharming Group, PT. Prodia Stem Cell Indonesia, Revalesio Corporation, Roche, Shin Poong Pharmaceutical, Shionogi & Co., Ltd., Silver Creek Pharmaceuticals, Supergene, Tasly Pharmaceutical, TrueBinding, Inc, ZZ Biotech, and many more.
Emerging and Marketed Acute Ischemic Stroke Therapies Covered in the Report Include:
-
Nelonemdaz: GNT Pharma
-
Tenecteplase: Genentech
-
SP-8203: Shin Poong Pharmaceutical
-
NONO-SC: NoNO Inc.
-
Glenzocimab: Acticor Biotech
-
DM199: DiaMedica Therapeutics
-
LT3001: Lumosa Therapeutics
-
Nerinetide: NoNO Inc.
-
BMS-986177/milvexian: Bristol Myers Squibb Company/Janssen Pharmaceuticals
-
Invimestrocel (Healios/Athersys
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Acute Ischemic Stroke Competitive Intelligence Analysis
4. Acute Ischemic Stroke Market Overview at a Glance
5. Acute Ischemic Stroke Disease Background and Overview
6. Acute Ischemic Stroke Patient Journey
7. Acute Ischemic Stroke Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Acute Ischemic Stroke Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Ischemic Stroke Unmet Needs
10. Key Endpoints of Acute Ischemic Stroke Treatment
11. Acute Ischemic Stroke Marketed Therapies
12. Acute Ischemic Stroke Emerging Drugs and Latest Therapeutic Advances
13. Acute Ischemic Stroke Seven Major Market Analysis
14. Attribute Analysis
15. Acute Ischemic Stroke Market Outlook (In US, EU5, and Japan)
16. Acute Ischemic Stroke Companies Active in the Market
17. Acute Ischemic Stroke Access and Reimbursement Overview
18. KOL Views on the Acute Ischemic Stroke Market
19. Acute Ischemic Stroke Market Drivers
20. Acute Ischemic Stroke Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/acute-ischemic-stroke-ais-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Idiopathic Interstitial Pneumonia Market
“Idiopathic Interstitial Pneumonia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Idiopathic Interstitial Pneumonia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Idiopathic Interstitial Pneumonia market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology